The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis

Carcinogenesis

Volumn 32, Issue 8, 2011, Pages 1162-1166

  Bigsby, Robert M ^a   Caperell Grant, Andrea ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D9; CYTOCHROME P450 3A16; CYTOCHROME P450 3A41; CYTOCHROME P450 4A12; CYTOCHROME P450 B13; DIETHYLNITROSAMINE; ELOV3 PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GAPDH PROTEIN; GROWTH HORMONE; LIVER PROTEIN; PROLACTIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE INACTIVATION; HORMONE RELEASE; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTECTION; SEX DIFFERENCE; WILD TYPE;

EID: 79961189898     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr094     Document Type: Article

References (64)

1. El-Serag,H.B. (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 127, S27-S34.
2. Shimizu,I. et al. (2007) Female hepatology: favorable role of estrogen in chronic liver diseasewith hepatitis B virus infection. World J. Gastroenterol., 13, 4295-4305.
3. Ohishi,W. et al. (2008) Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol. Biomarkers Prev., 17, 846-854.
4. Tanaka,K. et al. (2006) Cigarette smoking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among Japanese. Jpn. J. Clin. Oncol., 36, 445-456.
5. Marrero,J.A. et al. (2005) Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J. Hepatol., 42, 218-224.
6. Yu,M.C. et al. (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology, 127, S72-S78.
7. Fattovich,G. et al. (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127, S35-S50.
8. Hanigan,M. et al. (1993) Induction of three histochemically distinct populations of hepatic foci in C57BL/6J mice. Carcinogenesis, 14, 1035-1040.
9. Poole,T. et al. (1995) Hormonal and genetic interactions in murine hepatocarcinogenesis. Prog. Clin. Biol. Res., 391, 187-194.
10. Poole,T. et al. (1996) Strain dependent effects of sex hormones on hepatocarcinogenesis in mice. Carcinogenesis, 17, 191-196.
11. Kemp,C. et al. (1989) Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. Proc. Natl Acad. Sci. USA, 86, 7505-7509.
12. Nakatani,T. et al. (2001) Sex hormone dependency of diethylnitrosamineinduced liver tumors in mice and chemoprevention by leuprorelin. Jpn. J. Cancer Res., 92, 249-256.
13. Yamamoto,R. et al. (1995) Correlation between serum prolactin levels and hepatocellular tumorigenesis induced by 3'-methyl-4-dimethylaminoazobenzene in mice. Br. J. Cancer, 72, 17-21.
14. Ormandy,C.J. et al. (1998) Mouse prolactin receptor gene: genomic organization reveals alternative promoter usage and generation of isoforms via alternative 3'-exon splicing. DNA Cell Biol., 17, 761-770.
15. Bugni,J. et al. (2001) The little mutation suppresses DEN-induced hepatocarcinogenesis in mice and abrogates genetic and hormonal modulation of susceptibility. Carcinogenesis, 22, 1853-1862.
16. Colleoni,M. et al. (1995) Megestrol acetate in unresectable hepatocellular carcinoma. Tumori, 81, 351-353.
17. Chao,Y. et al. (1996) Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer, 77, 635-639.
18. GRETCH. (2004) Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology, 40, 1361-1369.
19. Ruden,D.M. et al. (2005) Hsp90 and environmental impacts on epigenetic states: a model for the trans-generational effects of diethylstibesterol on uterine development and cancer. Hum. Mol. Genet. 14 (suppl. 1) R149-R155.
20. Grese,T. et al. (1998) Selective estrogen receptor modulators (SERMs). Curr. Pharm. Des., 4, 71-92.
21. Bryant,H. et al. (1998) Selective estrogen receptor modulators: an alternative to hormone replacement therapy. [Review]. Proc. Soc. Exp. Biol. Med., 217, 45-52.
22. Fournier,B. et al. (2001) Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. J. Biol. Chem., 276, 35444-35449.
23. Yu,M. et al. (2000) Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J. Natl Cancer Inst., 92, 2023-2028.
24. Enmark,E. et al. (1997) Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab., 82, 4258-4265.
25. Kuiper,G. et al. (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA, 93, 5925-5930.
26. Lubahn,D.B. et al. (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl Acad. Sci. USA, 90, 11162-11166.
27. Steinmetz,R. et al. (1997) The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. Endocrinology, 138, 1780-1786.
28. Ulrich,E.M. et al. (2000) Environmentally relevant xenoestrogen tissue concentrations correlated to biological responses in mice. Environ. Health Perspect., 108, 973-977.
29. Bigsby,R.M. et al. (2009) Ovarian hormone modulation of radiation-induced cataractogenesis: dose-response studies. Invest. Ophthalmol. Vis. Sci., 50, 3304-3310.
30. Ormandy,C. et al. (1997) Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev., 11, 167-178.
31. Bouchard,B. et al. (1999) Immune system development and function in prolactin receptor-deficient mice. J. Immunol., 163, 576-582.
32. Sueyoshi,T. et al. (1999) Developmental action of estrogen receptor-alpha feminizes the growth hormone-Stat5b pathway and expression of Cyp2a4 and Cyp2d9 genes in mouse liver. Mol. Pharmacol., 56, 473-477.
33. Weiss,J. et al. (2008) Estrogen actions in the male reproductive system involve estrogen response element-independent pathways. Endocrinology, 149, 6198-6206.
34. Park,S.H. et al. (1999) Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J. Biol. Chem., 274, 7421-7430.
35. Jarukamjorn,K. et al. (2006) Modified expression of cytochrome P450 mRNAs by growth hormone in mouse liver. Toxicology, 219, 97-105.
36. Jarukamjorn,K. et al. (2006) Regulation of mouse hepatic CYP2D9 mRNA expression by growth and adrenal hormones. Drug Metab. Pharmacokinet., 21, 29-36.
37. Veldhuis,J.D. et al. (2006) Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocr. Rev., 27, 101-140.
38. Wauthier,V. et al. (2008) Sex-specific early growth hormone response genes in rat liver. Mol. Endocrinol., 22, 1962-1974.
39. Vidal,O. et al. (1999) Disproportional body growth in female estrogen receptor-alpha-inactivated mice. Biochem. Biophys. Res. Commun., 265, 569-571.
40. Lindberg,M.K. et al. (2001) Estrogen receptor specificity in the regulation of the skeleton in female mice. J. Endocrinol., 171, 229-236.
41. Baron,S. et al. (2007) Estrogen receptor alpha and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene. J. Biol. Chem., 282, 11732-11741.
42. Maeda,S. et al. (2005) IKKbeta couples hepatocyte death to cytokinedriven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell, 121, 977-990.
43. Sakurai,T. et al. (2006) Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl Acad. Sci. USA, 103, 10544-10551.
44. Naugler,W.E. et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 317, 121-124.
45. Sander,L.E. et al. (2007) Is interleukin-6 a gender-specific risk factor for liver cancer? Hepatology, 46, 1304-1305.
46. Prieto,J. (2008) Inflammation, HCC and sex: IL-6 in the centre of the triangle. J. Hepatol., 48, 380-381.
47. Yeh,S.H. et al. (2010) Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology, 78 (suppl. 1), 172-179.
48. Simpson,E.R. et al. (1997) Aromatase expression in health and disease. Recent Prog. Horm. Res., 52, 185-213. discussion 213-214.
49. Agarwal,V.R. et al. (1998) Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J. Clin. Endocrinol. Metab., 83, 1797-1800.
50. Castagnetta,L.A. et al. (2003) Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells. Cancer Res., 63, 5041-5045.
51. Granata,O.M. et al. (2006) Metabolic profiles of androgens in malignant human liver cell lines. Ann. N. Y. Acad. Sci., 1089, 262-267.
52. Donato,F. et al. (2002) Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am. J. Epidemiol., 155, 323-331.
53. Braunstein,G.D. (1999) Aromatase and gynecomastia. Endocr. Relat. Cancer, 6, 315-324.
54. Purohit,V. (2000) Can alcohol promote aromatization of androgens to estrogens? A review. Alcohol, 22, 123-127.
55. Bigsby,R.M. (2002) Synergistic tumor promoter effects of estrone and progesterone in methylnitrosourea-induced rat mammary cancer. Cancer Lett., 179, 113-119.
56. Banerjee,S.K. et al. (1997) Biphasic estrogen response on bovine adrenal medulla capillary endothelial cell adhesion, proliferation and tube formation. Mol. Cell. Biochem., 177, 97-105.
57. Parini,P. et al. (2000) Biphasic effects of the natural estrogen 17betaestradiol on hepatic cholesterol metabolism in intact female rats. Arterioscler. Thromb. Vasc. Biol., 20, 1817-1823.
58. Du Mond,J.W.Jr. et al. (2001) The biphasic stimulation of proliferation of Leydig cells by estrogen exposure. Int. J. Oncol., 18, 623-628.
59. Wagner,E.J. et al. (2001) Estrogen biphasically modifies hypothalamic GABAergic function concomitantly with negative and positive control of luteinizing hormone release. J. Neurosci., 21, 2085-2093.
60. Strom,J.O. et al. (2010) Different methods for administering 17betaestradiol to ovariectomized rats result in opposite effects on ischemic brain damage. BMC Neurosci., 11, 39.
61. Poole,T. et al. (1996) Two genes abrogate the inhibition of murine hepatocarcinogenesis by ovarian hormones. Proc. Natl Acad. Sci. USA, 93, 5848-5853.
62. Chiaverotti,T.A. et al. (2003) C57BR/cdJ hepatocarcinogen susceptibility genes act cell-autonomously in C57BR/cdJ,->C57BL/6J chimeras. Cancer Res., 63, 4914-4919.
63. Peychal,S.E. et al. (2009) Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6Mb on chromosome Carcinogenesis, 30, 879-885.
64. Ben-Jonathan,N. et al. (2008) What can we learn from rodents about prolactin in humans? Endocr. Rev., 29, 1-41.